A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Raxatrigine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms RELAY-1
- Sponsors Biogen; Convergence Pharmaceuticals
- 07 Nov 2017 Planned End Date changed from 30 Mar 2018 to 22 Aug 2018.
- 07 Nov 2017 Planned primary completion date changed from 30 Mar 2018 to 22 Aug 2018.
- 09 Oct 2017 Planned End Date changed from 15 Dec 2017 to 30 Mar 2018.